{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:24:13Z","timestamp":1784046253980,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1245\/s10434-023-14319-0","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T23:17:10Z","timestamp":1696547830000},"page":"8412-8418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer"],"prefix":"10.1245","volume":"30","author":[{"given":"Sara P.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audree B.","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8154-4848","authenticated-orcid":false,"given":"Minna K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"14319_CR1","first-page":"1013","volume":"60","author":"CI Szabo","year":"1997","unstructured":"Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997;60:1013\u201320.","journal-title":"Am J Hum Genet."},{"key":"14319_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10549-007-9600-1","volume":"108","author":"T Byrski","year":"2008","unstructured":"Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008;108:289\u201396.","journal-title":"Breast Cancer Res Treat."},{"key":"14319_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1012203917104","volume":"69","author":"J Chang","year":"2001","unstructured":"Chang J, Elledge RM. Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res Treat. 2001;69:101\u201313.","journal-title":"Breast Cancer Res Treat."},{"key":"14319_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.breast.2006.12.003","volume":"16","author":"A Musolino","year":"2007","unstructured":"Musolino A, Bella MA, Bortesi B, et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast. 2007;16:280\u201392.","journal-title":"Breast."},{"key":"14319_CR5","doi-asserted-by":"publisher","first-page":"100531","DOI":"10.1016\/j.esmoop.2022.100531","volume":"7","author":"G Tomasello","year":"2022","unstructured":"Tomasello G, Gambini D, Petrelli F, et al. Characterization of the HER2 status in BRCA-mutated breast cancer: a single-institutional series and systematic review with pooled analysis. ESMO Open. 2022;7:100531.","journal-title":"ESMO Open."},{"key":"14319_CR6","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1093\/jnci\/djh312","volume":"96","author":"RD Kennedy","year":"2004","unstructured":"Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96:1659\u201368.","journal-title":"J Natl Cancer Inst."},{"key":"14319_CR7","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/90.15.1138","volume":"90","author":"SR Lakhani","year":"1998","unstructured":"Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138\u201345.","journal-title":"J Natl Cancer Inst."},{"issue":"15 Suppl","key":"14319_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2021.39.15_suppl.579","volume":"39","author":"LKK Richters","year":"2021","unstructured":"Richters LKK, Gluz O, Weber-Lassalle N, et al. Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242). J Clin Oncol. 2021;39(15 Suppl):579.","journal-title":"J Clin Oncol."},{"key":"14319_CR9","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/cncr.29903","volume":"122","author":"PD Shah","year":"2016","unstructured":"Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status. Cancer. 2016;122:1178\u201384.","journal-title":"Cancer."},{"key":"14319_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13053-023-00249-1","volume":"21","author":"E Sivina","year":"2023","unstructured":"Sivina E, Blumberga L, Purkalne G, Irmejs A. Pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer: single-hospital experience. Hered Cancer Clin Pract. 2023;21:4.","journal-title":"Hered Cancer Clin Pract."},{"key":"14319_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10549-018-4797-8","volume":"171","author":"M Wunderle","year":"2018","unstructured":"Wunderle M, Gass P, H\u00e4berle L, et al. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. Breast Cancer Res Treat. 2018;171:85\u201394.","journal-title":"Breast Cancer Res Treat."},{"key":"14319_CR12","doi-asserted-by":"publisher","first-page":"8636","DOI":"10.1245\/s10434-021-10195-8","volume":"28","author":"SP Myers","year":"2021","unstructured":"Myers SP, Ahrendt GM, Lee JS, et al. Association of tumor molecular subtype and stage with breast and axillary pathologic complete response after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2021;28:8636\u201342.","journal-title":"Ann Surg Oncol."},{"key":"14319_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, et al. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:77\u2013102.","journal-title":"J Natl Compr Canc Netw."},{"key":"14319_CR14","first-page":"199","volume":"14","author":"S Bari","year":"2022","unstructured":"Bari S, Boulware D, Li J, et al. A real-world data retrospective cohort study of low estrogen receptor-positive early breast cancer: natural history and treatment outcomes. Breast Cancer Dove Med Press. 2022;14:199\u2013210.","journal-title":"Breast Cancer Dove Med Press."},{"key":"14319_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41416-021-01597-2","volume":"126","author":"YD Guzm\u00e1n-Arocho","year":"2022","unstructured":"Guzm\u00e1n-Arocho YD, Rosenberg SM, Garber JE, et al. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022;126:302\u20139.","journal-title":"Br J Cancer."},{"key":"14319_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.annonc.2021.08.1988","volume":"32","author":"S Schrodi","year":"2021","unstructured":"Schrodi S, Braun M, Andrulat A, et al. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol. 2021;32:1410\u201324.","journal-title":"Ann Oncol."},{"issue":"8","key":"14319_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"D Ho","year":"2011","unstructured":"Ho D, Imai K, King G, Stuart E. MatchIt: non parametric processing for parametric causal inference. J Stat Software. 2011;42(8):1\u201328.","journal-title":"J Stat Software."},{"key":"14319_CR18","first-page":"952","volume":"52","author":"SW Kim","year":"2009","unstructured":"Kim SW. Korean hereditary breast cancer. JKMA. 2009;52:952\u201362.","journal-title":"JKMA."},{"key":"14319_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/BD-2010-0306","volume":"32","author":"BN Peshkin","year":"2010","unstructured":"Peshkin BN, Alabek ML, Isaacs C. BRCA1\/2 mutations and triple-negative breast cancers. Breast Dis. 2010;32:25\u201333.","journal-title":"Breast Dis."},{"key":"14319_CR20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2020.0007","volume":"6","author":"E Pohl-Rescigno","year":"2020","unstructured":"Pohl-Rescigno E, Hauke J, Loibl S, et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncol. 2020;6:744\u20138.","journal-title":"JAMA Oncol."},{"key":"14319_CR21","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","volume":"32","author":"F Ades","year":"2014","unstructured":"Ades F, Zardavas D, Bozovic-Spasojevic I, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014;32:2794\u2013803.","journal-title":"J Clin Oncol."},{"key":"14319_CR22","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.ejso.2016.10.011","volume":"42","author":"C Criscitiello","year":"2016","unstructured":"Criscitiello C, Curigliano G, Burstein HJ, et al. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: are we losing the opportunity? Eur J Surg Oncol. 2016;42:1780\u20136.","journal-title":"Eur J Surg Oncol."},{"key":"14319_CR23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer Jr","year":"2022","unstructured":"Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250\u201368.","journal-title":"Ann Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14319-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T15:15:53Z","timestamp":1699197353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14319-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["14319"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14319-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}